|
1
|
Guo Y, Chen Z, Zhang L, Zhou F, Shi S,
Feng X, Li B, Meng X, Ma X, Luo M, et al: Distinctive microRNA
profiles relating to patient survival in esophageal squamous cell
carcinoma. Cancer Res. 68:26–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yamakuchi M, Lotterman CD, Bao C, Hruban
RH, Karim B, Mendell JT, Huso D and Lowenstein CJ: P53-induced
microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad
Sci USA. 107:6334–6339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
He J, Zhang W, Zhou Q, Zhao T, Song Y,
Chai L and Li Y: Low-expression of microRNA-107 inhibits cell
apoptosis in glioma by upregulation of SALL4. Int J Biochem Cell
Biol. 45:1962–1973. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou C, Li G, Zhou J, Han N, Liu Z and Yin
J: miR-107 activates ATR/Chk1 pathway and suppress cervical cancer
invasion by targeting MCL1. PLoS One. 9:e1118602014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen L, Zhang R, Li P, Liu Y, Qin K, Fa
ZQ, Liu YJ, Ke YQ and Jiang XD: P53-induced microRNA-107 inhibits
proliferation of glioma cells and down-regulates the expression of
CDK6 and Notch-2. Neurosci Lett. 534:327–332. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Feng L, Xie Y, Zhang H and Wu Y: miR-107
targets cyclin-dependent kinase 6 expression, induces cell cycle G1
arrest and inhibits invasion in gastric cancer cells. Med Oncol.
29:856–863. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee KH, Lotterman C, Karikari C, Omura N,
Feldmann G, Habbe N, Goggins MG, Mendell JT and Maitra A:
Epigenetic silencing of microRNA miR-107 regulates cyclin-dependent
kinase 6 expression in pancreatic cancer. Pancreatology. 9:293–301.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhong Z, Lv M and Chen J: Screening
differential circular RNA expression profiles reveals the
regulatory role of circTCF25-miR-103a-3p/miR-107-CDK6 pathway in
bladder carcinoma. Sci Rep. 6:309192016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takahashi Y, Forrest A, Maeno E, Hashimoto
T, Daub CO and Yasuda J: MiR-107 and MiR-185 can induce cell cycle
arrest in human non small cell lung cancer cell lines. PLoS One.
4:e66772009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Song N, Ma X, Li H, Zhang Y, Wang X, Zhou
P and Zhang X: microRNA-107 functions as a candidate tumor
suppressor gene in renal clear cell carcinoma involving multiple
genes. Urol Oncol. 33:205.e1–205.e11. 2015. View Article : Google Scholar
|
|
11
|
Xia H, Li Y and Lv X: MicroRNA-107
inhibits tumor growth and metastasis by targeting the BDNF-mediated
PI3K/AKT pathway in human non-small cell lung cancer. Int J Oncol.
49:1325–1333. 2016.PubMed/NCBI
|
|
12
|
Che LF, Shao SF and Wang LX:
Downregulation of CCR5 inhibits the proliferation and invasion of
cervical cancer cells and is regulated by microRNA-107. Exp Ther
Med. 11:503–509. 2016.PubMed/NCBI
|
|
13
|
Wang WX, Kyprianou N, Wang X and Nelson
PT: Dysregulation of the mitogen granulin in human cancer through
the miR-15/107 microRNA gene group. Cancer Res. 70:9137–9142. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song YQ, Ma XH, Ma GL, Lin B, Liu C, Deng
QJ and Lv WP: MicroRNA-107 promotes proliferation of gastric cancer
cells by targeting cyclin dependent kinase 8. Diagn Pathol.
9:1642014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen PS, Su JL, Cha ST, Tarn WY, Wang MY,
Hsu HC, Lin MT, Chu CY, Hua KT, Chen CN, et al: miR-107 promotes
tumor progression by targeting the let-7 microRNA in mice and
humans. J Clin Invest. 121:3442–3455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moncini S, Salvi A, Zuccotti P, Viero G,
Quattrone A, Barlati S, De Petro G, Venturin M and Riva P: The role
of miR-103 and miR-107 in regulation of CDK5R1 expression and in
cellular migration. PLoS One. 6:e200382011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Z, Zhang L, Yin ZY, Fan XL, Hu B,
Wang LQ and Zhang D: miR-107 regulates cisplatin chemosensitivity
of A549 non-small cell lung cancer cell line by targeting cyclin
dependent kinase 8. Int J Clin Exp Pathol. 7:7236–7241.
2014.PubMed/NCBI
|
|
18
|
Datta J, Smith A, Lang JC, Islam M, Dutt
D, Teknos TN and Pan Q: microRNA-107 functions as a candidate
tumor-suppressor gene in head and neck squamous cell carcinoma by
downregulation of protein kinase Cε. Oncogene. 31:4045–4053. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Piao L, Zhang M, Datta J, Xie X, Su T, Li
H, Teknos TN and Pan Q: Lipid-based nanoparticle delivery of
Pre-miR-107 inhibits the tumorigenicity of head and neck squamous
cell carcinoma. Mol Ther. 20:1261–1269. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang M, Wang X, Li W and Cui Y: miR-107
and miR-25 simultaneously target LATS2 and regulate proliferation
and invasion of gastric adenocarcinoma (GAC) cells. Biochem Biophys
Res Commun. 460:806–812. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sharma P, Saraya A, Gupta P and Sharma R:
Decreased levels of circulating and tissue miR-107 in human
esophageal cancer. Biomarkers. 18:322–330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tao J, Ji J, Li X, Ding N, Wu H, Liu Y,
Wang XW, Calvisi DF, Song G and Chen X: Distinct anti-oncogenic
effect of various microRNAs in different mouse models of liver
cancer. Oncotarget. 6:6977–6988. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Martello G, Rosato A, Ferrari F, Manfrin
A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T,
et al: A microRNA targeting Dicer for metastasis control. Cell.
141:1195–1207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li X, Zhang Y, Shi Y, Dong G, Liang J, Han
Y, Wang X, Zhao Q, Ding J, Wu K, et al: MicroRNA-107, an oncogene
microRNA that regulates tumour invasion and metastasis by targeting
DICER1 in gastric cancer. J Cell Mol Med. 15:1887–1895. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cui J, Mo J, Luo M, Yu Q, Zhou S, Li T,
Zhang Y and Luo W: c-Myc-activated long non-coding RNA H19
downregulates miR-107 and promotes cell cycle progression of
non-small cell lung cancer. Int J Clin Exp Pathol. 8:12400–12409.
2015.PubMed/NCBI
|
|
26
|
Li XY, Luo QF, Wei CK, Li DF, Li J and
Fang L: MiRNA-107 inhibits proliferation and migration by targeting
CDK8 in breast cancer. Int J Clin Exp Med. 7:32–40. 2014.PubMed/NCBI
|
|
27
|
Stückrath I, Rack B, Janni W, Jäger B,
Pantel K and Schwarzenbach H: Aberrant plasma levels of circulating
miR-16, miR-107, miR-130a and miR-146a are associated with lymph
node metastasis and receptor status of breast cancer patients.
Oncotarget. 6:13387–13401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Orgaz JL, Herraiz C and Sanz-Moreno V: Rho
GTPases modulate malignant transformation of tumor cells. Small
GTPases. 5:e290192014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stengel K and Zheng Y: Cdc42 in oncogenic
transformation, invasion, and tumorigenesis. Cell Signal.
23:1415–1423. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu Y, Wang Y, Zhang Y, Miao Y, Zhao Y,
Zhang PX, Jiang GY, Zhang JY, Han Y, Lin XY, et al: Abnormal
expression of p120-catenin, E-cadherin, and small GTPases is
significantly associated with malignant phenotype of human lung
cancer. Lung Cancer. 63:375–382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Del Gómez Pulgar T, Valdés-Mora F, Bandrés
E, Pérez-Palacios R, Espina C, Cejas P, García-Cabezas MA, Nistal
M, Casado E, González-Barón M, et al: Cdc42 is highly expressed in
colorectal adenocarcinoma and downregulates ID4 through an
epigenetic mechanism. Int J Oncol. 33:185–193. 2008.PubMed/NCBI
|
|
32
|
Tucci MG, Lucarini G, Brancorsini D, Zizzi
A, Pugnaloni A, Giacchetti A, Ricotti G and Biagini G: Involvement
of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and
prognosis of cutaneous melanoma. Br J Dermatol. 157:1212–1216.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fritz G, Brachetti C, Bahlmann F, Schmidt
M and Kaina B: Rho GTPases in human breast tumours: Expression and
mutation analyses and correlation with clinical parameters. Br J
Cancer. 87:635–644. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kamai T, Yamanishi T, Shirataki H, Takagi
K, Asami H, Ito Y and Yoshida K: Overexpression of RhoA, Rac1, and
Cdc42 GTPases is associated with progression in testicular cancer.
Clin Cancer Res. 10:4799–4805. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Feng JG, Liu Q, Qin X, Geng YH, Zheng ST,
Liu T, Sheyhidin I and Lu XM: Clinicopathological pattern and
Annexin A2 and Cdc42 status in patients presenting with
differentiation and lymph node metastasis of esophageal squamous
cell carcinomas. Mol Biol Rep. 39:1267–1274. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu Z, Feng JG, Tuersun A, Liu T, Liu H,
Liu Q, Zheng ST, Huang CG, Lv GD, Sheyhidin I, et al: Proteomic
identification of differentially-expressed proteins in esophageal
cancer in three ethnic groups in Xinjiang. Mol Biol Rep.
38:3261–3269. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ridley AJ: Rho GTPase signalling in cell
migration. Curr Opin Cell Biol. 36:103–112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang XY, Gan MX, Li Y, Zhan WH, Han TY,
Han XJ, Cheng JQ and Wang JB: Cdc42 induces EGF receptor protein
accumulation and promotes EGF receptor nuclear transport and
cellular transformation. FEBS Lett. 589:255–262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hirsch DS, Shen Y and Wu WJ: Growth and
motility inhibition of breast cancer cells by epidermal growth
factor receptor degradation is correlated with inactivation of
Cdc42. Cancer Res. 66:3523–3530. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mahajan K and Mahajan NP: Shepherding AKT
and androgen receptor by Ack1 tyrosine kinase. J Cell Physiol.
224:327–333. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tu S and Cerione RA: Cdc42 is a substrate
for caspases and influences Fas-induced apoptosis. J Biol Chem.
276:19656–19663. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xiao B, Chen D, Luo S, Hao W, Jing F, Liu
T, Wang S, Geng Y, Li L, Xu W, et al: Extracellular translationally
controlled tumor protein promotes colorectal cancer invasion and
metastasis through Cdc42/JNK/MMP9 signaling. Oncotarget.
7:50057–50073. 2016.PubMed/NCBI
|
